1. Introduction {#s0005}
===============

Stroke is the 2nd leading cause of death worldwide. It is also the leading cause of disability in adults, with 20% of stroke survivors needing help to walk and being dependent on others to perform daily tasks. Stroke survivors therefore require significant social and healthcare resources [@bb0005].

In the elderly population of 15 European countries during the year 2000, estimates showed 2,700,000 recurrent stroke cases, and 536,000 incident stroke cases per year [@bb0010]. The total number of deaths due to stroke in the total European Union (EU) members is estimated at 508,000/year. Given that age is one of most important risk factors for stroke, the aging of the world population implies a growing number of people at risk. An international comparison of stroke cost studies showed that 0.27% of domestic product was spent on stroke care by national health systems, and stroke care accounted for approx. 3% of total healthcare expenditure [@bb0015].

1.1. Stroke Recurrence {#s0010}
----------------------

The risk of ischemic stroke recurrence after a first stroke is high, especially in the early stages, being around 6--12% within the first year of the initial stroke [@bb0020]. Moreover, stroke patients also have a high risk of developing other vascular diseases such as acute myocardial infarction and vascular death. Data suggest that within 10 years of having an ischemic stroke or Transient Ischemic Attack (TIA), around 60% of patients will die and 54% will experience a new vascular event.

1.2. Stroke Functional Outcome {#s0015}
------------------------------

The variability in functional status and neurological outcome after stroke can be influenced by many factors, including age, haemorrhagic transformation (HT), infarct size and location, or the efficiency of revascularisation (by thrombolytic drugs or mechanical thrombectomy) [@bb0025], [@bb0030]. Results from previous studies suggest that basal glucose, age, hypertension and arterial revascularisation success accounted for 33% of the variability in neurological outcome during the acute phase of stroke (at 24 h). However, 57% of the neurological variability remains unexplained. In addition, 25% of neurological outcome could be explained by common polymorphisms or single nucleotide polymorphisms (SNPs) [@bb0035].

1.3. Stroke Genetics {#s0020}
--------------------

Stroke is influenced by genetic risk factors. These genetic risk factors can affect stroke occurrence, acute outcome, long-term outcome and vascular recurrence, among others. Interestingly, different molecular pathways modulate these processes, suggesting that different genetic risk factors influence these processes.

Different Genome Wide Association studies (GWAs) have been performed in ischemic stroke and different loci have been associated with the risk of suffering an ischemic stroke. Specifically, 3 genes have been associated with atherothrombotic stroke subtype (HDAC9, CDKN (locus 9p21) and TSPAN2), 2 genes with cardioembolic stroke subtype (PITX2 and ZFHX3), and 2 genes with young strokes (ABO and MMP12). Other GWAs analyses have found other genes and loci associated with stroke (PRKCH, NINJ and genetic locus 6p21.1), although further studies are needed to confirm those results [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085].

In relation to stroke recurrence several studies in Asian populations [@bb0090], [@bb0095] associations of *ANRIL* and *NINJ2* polymorphisms with vascular recurrence. Other studies in Caucasian populations found associations between *CRP* and *MGP* polymorphisms and recurrent stroke [@bb0020], [@bb0100]. However, other studies have not observed those associations [@bb0105].

Different polymorphisms in the genes MMP2, COX-2, GPII, and TP53 have been associated with post-stroke outcome [@bb0110], [@bb0115], [@bb0120], although these results have not been consistently replicated.

1.4. Epigenetics {#s0025}
----------------

The risk associated with the genetic background in stroke is in the order of 37.9% [@bb0125], [@bb0130]. However, the genetic risk associated with the variants found to date only account for 5--10% of that genetic risk [@bb0125]. Therefore, there are more genes and heritable risk factors associated with stroke that have not yet been discovered. One of these possible heritable changes could be associated with epigenetic modifications.

Epigenetic mechanisms are known to alter gene expression or cellular phenotype [@bb0135].

There are three major components of epigenetic modification: a) methylation, b) histone modifications and c) non-coding ribonucleic acid (RNA) interference. Both methylation and histone modifications join hands to provide a dynamic epigenetic code. Along with non-coding RNAs (ncRNAs) and certain interacting proteins, these modifications regulate the transcription process.

### 1.4.1. Methylation {#s0030}

DNA methylation and modifications in histone proteins are the most intensively studied among the major epigenetic modifications. DNA methylation occurs when a methyl group is added to a cytosine nucleotide that precedes guanines (so-called CpG islands or CpG sites).

A CpG island may be defined as the DNA region of at least 500 base pairs with a CG content of \> 55% [@bb0140]. Methylation of CpG islands is catalysed by a family of enzymes, the DNA methyl transferases (DNMTs). DNMT1 maintains cytosine methylation through mitotic and meiotic cell divisions. Methylation of a CpG island within gene promoters is commonly associated with repressed gene expression, as it impedes the binding of transcription factors.

### 1.4.2. Other Epigenetic Modifications {#s0035}

Post-translational histone modifications, such as methylation and acetylation of lysine residues on histone tails, affect gene expression mainly by altering chromatin structure [@bb0135]. Acetylation is brought about by histone acetyltransferase (HATs) enzymes and deacetylation by histone deacetylases (HDACs) [@bb0145], [@bb0150].

Small non-coding RNAs (sncRNAs) are epigenetic elements (\< 30 nucleotides) with a post-transcriptional biological function. The major components of the sncRNA family, the microRNAs (miRNAs), generally interact specifically with the 3′ untranslated region of a target mRNA to induce its cleavage and degradation, or via a translational repression of gene expression [@bb0155], [@bb0160].

Epigenetic mechanisms are known to alter gene expression [@bb0135]. However, other underlying mechanisms such as genetic variations could modify DNA CpG sites modifying the epigenetic regulation of genes [@bb0165]. Knowing these mechanisms could be important in finding new treatments for stroke and other cardiovascular diseases [@bb0170].

1.5. Epigenome-Wide Association Studies (EWAS). Technical Aspects of the Methylation Chips {#s0040}
------------------------------------------------------------------------------------------

Genome-wide association studies (GWAS) have been powerful tools in the identification of the most common genetic variants associated with a multitude of complex traits including common diseases. In contrast, the systematic assessment of epigenetic variation has lagged behind. Technological advances in high-throughput DNA analysis have facilitated the genome-wide examination of epigenetic modifications, primarily DNA methylation. Epigenome-wide association studies (EWAS) have provided systematic, large-scale association testing with disease phenotypes. The latest EWAS arrays (the Infinium EPIC HumanMethylation BeadChip (Illumina)) can detect the methylation levels of \> 800,000 CpG sites across the genome.

Numerous diseases, exposures and lifestyle factors have been investigated by EWAS, with several significant associations now identified. However, much like the GWAS studies, EWAS are likely to require large international consortium-based approaches to reach the numbers of subjects, and statistical and scientific rigour, required for robust findings.

### 1.5.1. Tissue-Specific Methylation {#s0045}

DNA methylation is strongly influenced by the tissue analysed and the environment. In fact, epigenetics is one of the metabolic factors that regulate the different expression pattern of the cells and tissues. Consequently, epigenetic studies should be performed in the key tissue for the disease or the condition. In addition, in the case of blood samples there are different cell types with different DNA methylation pattern. This should be taken into consideration before EWAs analysis in order to normalise the results.

Taking into consideration the role of genetics in the risk of stroke but also the outcome after a stroke, DNA methylation could be associated with the occurrence of stroke, with stroke recurrence and with functional outcome after stroke.

2. DNA Methylation in Stroke {#s0050}
============================

2.1. Methods {#s0055}
------------

An extensive literature search was performed, up to October 2017, on PubMed with the following combination of key words: "Epigenetics and stroke" and "EWAs and stroke". For the combination of "Epigenetics and stroke" we found 128 papers and 4 for the combination of "EWAs and stroke". Three papers were common between the two combinations of words ([Fig. 1](#f0005){ref-type="fig"}). Two researchers independently check the papers. We selected the papers that 1) were performed using human samples and an EWAs approach, and 2) papers that analysed the global methylation pattern of stroke patients. Finally, eight papers were included in the current revision ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Work flow showing the selection of the studies included in the present review.Fig. 1

In addition, we included examples of other diseases or studies in animal models that support the results observed in stroke.

2.2. Stroke DNA Methylation Risk Factor {#s0060}
---------------------------------------

Epigenetic modifications, specifically DNA methylation, are influenced by environmental factors and are heritable modifications. It has been observed that different levels of DNA methylation are associated with the risk of diseases such as cancer, diabetes, obesity, atherosclerosis or arterial hypertension [@bb0175].

Human and mouse studies have observed global DNA hypermethylation of cytosines in CpGs as an accompanying feature of atherosclerosis [@bb0175], [@bb0180], [@bb0185]. Indeed, a positive correlation between DNA methylation and atherosclerotic lesion grade was discovered by using genome-wide DNA methylation sequencing (i.e., bisulphite sequencing) of healthy and atherosclerotic human aortas [@bb0175], [@bb0190] and confirmed by EWAS validation. Differentially methylated regions within the loci of cardiovascular disease associated genes in endothelial cells isolated from atherothrombotic regions of porcine aortas were also discovered using methylated DNA sequencing [@bb0195].

Furthermore, global DNA hypermethylation has been observed in peripheral lymphocytes of patients with cardiovascular disease, and may be linked to the inflammatory activity of innate immune cells [@bb0200].

Interestingly, global methylation was not found to be associated with stroke subtypes measured by luminometric methylation assay (LUMA) of blood DNA samples [@bb0205]. In contrast, other studies have observed an association of global hypomethylation and higher risk of stroke [@bb0210].

A recent study analysed a Swedish population of 729 subjects, 48 of them with myocardial infarction and 27 with previous stroke, using an EWAs approach. The authors found a different methylation pattern in 211 CpG sites associated with myocardial infarction. However, they did not find any significant association with stroke [@bb0215].

The DNA methylation levels change during aging, and there is usually a global hypermethylation in older people. In fact, is possible to calculate the biological age using the methylation levels of several CpG sites.

In the field of stroke, it has been shown that the biological age (different from chronological age) of stroke patients measured by DNA methylation is different between cases suffering stroke and healthy controls. The stroke patients were biologically older than healthy controls [@bb0220]. The authors of this study calculated the "epigenetic age" or "biological age" using the DNAm levels of whole-blood DNA and using the Hannum method [@bb0220], [@bb0225]. This method is based on the methylation levels from 71 methylation probes from a 450 K EWAS Methylation array.

The authors analysed a group of 123 stroke cases and controls matched by chronological age and they found that ischemic stroke patients were biologically on average 2.5 years older than healthy controls, indicating that biological age measured with DNA methylation levels could be a stronger risk factor for ischemic stroke than chronological age.

2.3. DNA Methylation and Stroke Recurrence {#s0065}
------------------------------------------

Several independent papers have observed the role of DNA methylation in the risk of new vascular events (vascular recurrence) after a first ischemic stroke. Hypomethylation of the *ABCB1* promoter has been associated with poor response to clopidogrel in Chinese ischemic stroke patients with the *CYP2C19\*1/\*1* genotype [@bb0230]. ABCC3, another member of the ABC family, has been associated with the efflux of clopidogrel and its antiplatelet activity [@bb0235], [@bb0240]. However, *ABCC3* promoter methylation and down-regulation of *ABCC3* mRNA had no significant association with clopidogrel response [@bb0245].

A recent epigenome-wide study revealed that lower methylation of cg03548645 within the *TRAF3* body was associated with increased platelet aggregation and vascular recurrence in ischemic stroke patients treated with clopidogrel [@bb0250]. The authors hypothesised that higher *TRAF3* expression due to decreased methylation may lead to an increase in CD40 signal pathway interfered platelet-platelet interactions [@bb0255], [@bb0260].

In another study from the same group they observed that higher methylation levels of cg04985020 (*PPM1A* gene) were associated with vascular recurrence in patients treated with aspirin [@bb0265]. They analysed 38 ischemic stroke patients with an EWAS array and detected \> 450,000 CpG sites. Secondly, they performed a replication analysis in 289 new ischemic stroke patients. This analysis confirmed that the role of *PPM1A* methylation levels in the risk of new vascular events after stroke involves the regulation of transforming growth factor. They hypothesised that higher methylation of *PPM1A* was associated with (TGF)-β1 signalling and plasminogen activator inhibitor-1 transcription [@bb0270].

2.4. DNA Methylation of Functional Outcome {#s0070}
------------------------------------------

In relation to functional outcome, only a couple of studies have been performed to evaluate the association of DNA methylation levels and post-stroke functional outcome. However, it seems that DNA methylation could have an important role in this condition. In studies with animal models of ischemia, it has been observed that epigenetic mechanisms are associated with neurological outcome, thereby indicating that epigenetic processes may play a significant role in post-stroke outcome [@bb0275].

Pilot studies with 700 stroke patients and EWAS data that analysed 450,000 CpG islands across the genome showed that several genes had an altered methylation associated with neurological outcome after stroke [@bb0280]. However, these results should be replicated in independent cohorts.

In addition, a recently published paper observed that biological age, as measured by DNA methylation, was associated with poor functional outcome in stroke patients [@bb0285]. The authors calculated the epigenetic age as the sum of the beta values multiplied by the reported effect sizes following a previously reported protocol [@bb0220], [@bb0225]. They observed that this epigenetic age was a better predictor of functional stroke outcome at the third month compared to chronological age. Interestingly, the same authors observed an association of epigenetic age with stroke risk [@bb0220].

2.5. Challenges and Solutions for Studying Epigenetics in Stroke Patients {#s0075}
-------------------------------------------------------------------------

Epigenetic analysis in stroke entails the challenge of testing the key tissue for the disease. It is difficult to study brain necrotic samples or human blood vessels; consequently, epigenetics studies are performed on blood samples. This could be a problem due to: a) the tissue not being the key tissue for the disease, and b) the variability in the cell composition of the blood samples.

For the first point, transcriptomic and proteomic analyses have demonstrated that blood is an important tissue for stroke, probably due to the role of leukocytes in the inflammation process of atherosclerosis and neurological outcome after stroke [@bb0290], [@bb0295].

For the second point, the epigenetic results can be normalised whenever the cell count data for a sample is available. In addition, for EWAS analysis, R packages (WateRmelon) [@bb0300], [@bb0305] incorporate statistical normalization for blood sample results.

3. Summary and Outlook {#s0080}
======================

The use of epigenetics studies in stroke is an emerging field of interest. It seems that epigenetics plays an important role in this disease in different stages, prior to the ischemic attack and after the ischemic stroke. Specifically, DNA methylation could be associated with the risk of stroke, with stroke recurrence and with the functional outcome after stroke.

DNA methylation is a modifiable regulation; it is possible that in the future methylated or unmethylated genes could be a drug target for stroke treatment. In fact, there are now effective neuroprotective drugs that can be used to improve neurological worsening after stroke. New treatments focusing on this end-point could be very interesting for clinical practice.

However, more studies increasing the sample size with international collaboration and robust replications will be needed to find the epigenetic regulations that could be associated with stroke.

Several studies are currently ongoing in this field, mainly using EWAS arrays due to the option to perform genome-wide unbiased approaches. These studies will highlight the role of DNA methylation in stroke ([Table 1](#t0005){ref-type="table"}).Table 1Summary of the most interesting epigenetics studies performed in stroke.Table 1Author (reference)Epigenetics associationStroke riskStroke recurrenceStroke functional outcomeZaina et al. [@bb0175]Positive correlation between DNA methylation and atherosclerotic lesion gradeYesnanaValencia-Morales et al. [@bb0190]Correlation between histological grade of aortic stenosis and DNA methylationYesnanaSoriano et al. [@bb0205]Global MethylationNonanaSoriano et al. [@bb0220]"Biological age" measured with DNA methylationYesnanaYang et al. [@bb0230]Hypomethylation of the *ABCB1* promoter has been associated with poor response to clopidogrel in Chinese ischemic stroke patients with the *CYP2C19\*1/\*1* genotypenaYesnaJie et al. [@bb0245]*ABCC3* promoter methylation and down-regulation of *ABCC3* mRNA had no significant association with clopidogrel responsenaNonaGallego-Fabrega et al. [@bb0250]Lower methylation of cg03548645 within the *TRAF3* body was associated with increased platelet aggregation and vascular recurrence in ischemic stroke patients treated with clopidogrelnaYesnaGallego-Fabrega et al. [@bb0265]Higher methylation levels of cg04985020 (*PPM1A* gene) were associated with vascular recurrence in patients treated with aspirinnaYesnaCullell et al. [@bb0280]Pilot studies with 700 stroke patients and EWAS data that analysed 450,000 CpG islands across the genome, showed that several genes had an altered methylation associated with neurological outcome after strokenanaYesSoriano-Tarrega et al. [@bb0285]Biological age, as measured by DNA methylation, was associated with poor functional outcome in stroke patientsnanaYesRask-Andersen et al. [@bb0215]EWAs performed in 729 subjects (strokes n = 27) did not find significant associations with stroke.Nonana

In addition, epigenetic treatment has been approved by regulatory agencies for several conditions. The relevance of epigenetic treatment in haematological malignancies (leukemia, lymphomas, myelodysplastic syndromes, myeloma) have already been described in detail [@bb0310]. Several agents that interfere with DNA methylation-demethylation and histones acetylation/deacetylation have been studied, and some (such as azacytidine, decitabine, valproic acid and vorinostat) are already in clinical use. In the current clinical setting, there are two classes of epigenetic drugs, which act through inhibition of the enzymatic activities responsible for epigenetic transcriptional silencing: DNMTs and HDACs. Importantly, one type of HDAC, HDAC9, has been associated with stroke risk in several genome wide studies [@bb0045], [@bb0065]. In addition, recent papers using HDACs inhibitors have been associated with better functional recovery in ischemic models of stroke [@bb0315]. This type of drugs could be tested in stroke in the future if epigenetic associations with stroke risk and stroke outcome are confirmed.
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